Neurology® Podcast Revised Criteria for Diagnosis and Staging of Alzheimer Disease
Oct 24, 2024
Dr. Clifford R. Jack Jr, a leading Alzheimer's disease researcher from the Mayo Clinic, shares cutting-edge insights into diagnosing and staging Alzheimer’s disease. The discussion highlights the pivotal role of biomarkers, moving beyond traditional dementia symptoms. Jack emphasizes the classification of core biomarkers related to A-beta and tau proteins, advocating for their use in early intervention. He also outlines future directions that blend clinical practice with scientific advancement, aiming for improved patient care and treatment outcomes.
AI Snips
Chapters
Transcript
Episode notes
Alzheimer's Definition
- Alzheimer's disease should be biologically defined, focusing on plaques and tangles.
- It's a specific disease process, not synonymous with dementia or cognitive impairment.
Biomarker Use in Practice
- Biomarkers are not yet widely used in clinical practice but hold promise.
- Plasma biomarkers, specifically, are expected to revolutionize Alzheimer's diagnosis and management.
Biomarker Categories
- Core 1 biomarkers (A-beta proteinopathy) are used for diagnosis at any stage, as they remain abnormal.
- Core 2 biomarkers (tau proteinopathy) are used for staging alongside Core 1, becoming abnormal later.